Clinical trials: immunohistochemistry staining method, completed
Surgical Retinal
CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases
The aims of this study were to analyze CD160 expression in both normal and pathological eyes from human adults to evaluate association between CD160 presence on endothelial cells from blood vessels and retinal vascular disease
- Trial name
- NEOVASC-CD160 (NCT03940664)
- Testing
- immunohistochemistry on Formalin fixed and paraffin embedded blocks
- Where
- France
- Volunteers
- 75 people
- Sponsor
- CHU de Reims
Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell
A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens
The primary purpose of this non-interventional, multinational study is to assess the feasibility of assessing PD-L1 protein expression on cytological samples as a surrogate for histological samples obtained from participants with…
- Trial name
- NCT03092739
- Testing
- PD-L1 Immunocytochemistry (ICC), PD-L1 Immunohistochemistry (IHC)
- Where
- 8 sites in Czechia, Germany and 4 more
- Volunteers
- 184 people
- Sponsor
- Hoffmann-La Roche
Bladder (Urothelial, Transitional Cell) Cancer
Evaluation of ENPP1 Expression and Immune Response in Bladder Cancer Patients
This study aims to investigate the role of ENPP1 in bladder cancer (BC), specifically focusing on its impact on immune evasion, chemoresistance, and prognosis.
- Trial name
- ENPP1-BC (NCT06657755)
- Testing
- Immunohistochemistry
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Lanzhou University Second Hospital
Non Small-cell Lung Cancer
Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK)
Because ALK-positive lung cancer constitutes less than 5% of all lung cancers, it is critically important to select those patients who are more likely to have the ALK mutation.
- Trial name
- ALK (NCT01662635)
- Where
- Mexico
- Volunteers
- 230 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
HER2 Low Breast Carcinoma
Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients
In this large-scale cross-sectional study, we evaluated disease-free survival (DFS), overall survival (OS), and clinicopathological characteristics of BC patients from 1991 to 2022, retrospectively.
- Trial name
- NCT05754047
- Testing
- immunohistochemistry (IHC) and in situ hybridization (ISH) Test
- Volunteers
- 3,582 people
- Sponsor
- Mahdis Bayat
Clear Cell Renal Cell Carcinoma (ccRCC)
Evaluation of HPGD and SCLO2A1 Expression in Clear Cell Renal Cell Carcinoma Patients
This study aims to investigate the role of HPGD in clear cell renal cell carcinoma (ccRCC). Specifically, it will focus on HPGD's impact on proliferation, epithelial-mesenchymal transition (EMT), and prognosis.
- Trial name
- HPGD-ccRCC (NCT06778538)
- Testing
- Immunohistochemistry; WB; PCR
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shang Panfeng
Thyroid Nodule
PACE4 in Thyroid Cancer
The investigation of thyroid nodules is limited by the fact that up to 49% of the fine needle aspirations (FNA) performed are of "indeterminate cytological signification".
- Trial name
- NCT03160482
- Testing
- Immunohistochemistry
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- Robert Day
Unspecified Adult Solid Tumor, Protocol Specific
SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: SB939 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of SB939 in treating patients with locally…
- Trial name
- NCT00504296
- Testing
- HDAC inhibitor SB939, immunoenzyme technique, immunohistochemistry staining method
- Where
- 2 sites in Canada
- Volunteers
- 39 people
- Sponsor
- NCIC Clinical Trials Group
Esophagus Cancer, Adenocarcinoma
Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer
The aim of this study is to investigate urokinase Plasminogen Activator Receptor (uPAR) microexpression in gastroesophageal cancer (adenocarcinomas) both qualitatively and semi-quantitatively and to evaluate if it offers a…
- Trial name
- NCT04669951
- Testing
- uPAR immunohistochemistry
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Michael Patrick Achiam
Non Small Cell Lung Cancer
Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung Cancer (NSCLC)
Aim of the study is to evaluated the role of IGF1R and p95HER2 on prognosis in radically resected non small cell lung cancer patients The primary objective is to correlate the expression of IGF1R and p95HER2 with survival.
- Trial name
- NCT00763607
- Testing
- Protein expression by immunohistochemistry and immunofluorescence
- Where
- Italy
- Volunteers
- 454 people
- Sponsor
- Armando Santoro, MD
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma
PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS
This is a multi-center, open-label, Phase 0 substudy designed to evaluate the ability of pembrolizumab, alone and in combination with MK-0482 or MK-4830, to elicit pharmacodynamic changes suggestive of antitumor immune activation…
- Trial name
- NCT06413095
- Testing
- Pembrolizumab, MK-0482 + Pembrolizumab, MK-4830 + Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 13 people
- Sponsor
- Presage Biosciences
Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma
Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma
This clinical trial is a multicentric prospective study to assess the clinical and prognostic value of sarcopenia in patients older than 70 years with diffuse large B-cell lymphoma.
- Trial name
- SARCOPENIE (NCT01715961)
- Testing
- anthropometric measurement
- Where
- France
- Volunteers
- 98 people
- Sponsor
- Centre Henri Becquerel
Lymphoma
S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients respond to treatment.
- Trial name
- NCT00896922
- Testing
- microarray analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Volunteers
- 180 people
- Sponsor
- SWOG Cancer Research Network
Primary Aldosteronism, Primary Aldosteronism Due to Aldosterone Producing Adenoma
A Novel and Efficient Biochemical Screening Strategy for Glucocorticoid-Remediable Aldosteronism: Combined 1-mg Overnight Dexamethasone Suppression Test and Steroid Profile
This prospective observational study evaluates a simplified biochemical screening strategy to differentiate Glucocorticoid-Remediable Aldosteronism (GRA) from Aldosterone-Producing Adenoma (APA).
- Trial name
- NCT07700888
- Testing
- 1 mg overnight dexamethasone inhibition test
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College Hospital
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer
RATIONALE: Everolimus may stop the growth of stomach or esophageal cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, and oxaliplatin, work in different ways to stop…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT01231399
- Testing
- fluorouracil, leucovorin calcium, oxaliplatin
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Currently patients with breast cancer are treated with one of several very similar combinations of drugs.
- Trial name
- NCT00017095
- Testing
- filgrastim, cyclophosphamide, docetaxel
- Where
- 39 sites in Belgium, France and 7 more
- Volunteers
- 1,856 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Unspecified Adult Solid Tumor, Protocol Specific
Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00714181
- Testing
- hydroxychloroquine, temozolomide, TdT-mediated dUTP nick end labeling assay
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Melanoma (Skin)
ABT-510 in Treating Patients With Metastatic Melanoma
RATIONALE: ABT-510 may stop the growth of melanoma by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well giving ABT-510 works in treating patients with metastatic melanoma.
- Trial name
- NCT00602199
- Testing
- ABT-510, immunoenzyme technique, immunohistochemistry staining method
- Volunteers
- 42 people
- Sponsor
- Mayo Clinic
Soft Tissue Sarcoma Adult
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
- Trial name
- NCT03056599
- Testing
- Multiple drug microinjection, CIVO device
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Presage Biosciences
Cancer of Colon
Significance of Immunohistochemical Expression of Fascin-1 in Colorectal Carcinoma
Colorectal carcinoma is a major health problem. As a malignant tumor, the malignant potential of colorectal carcinoma is based mainly on its ability to metastasis to different sites.
- Trial name
- NCT05553080
- Testing
- Immunohistochemistry
- Where
- 2 sites in Egypt
- Volunteers
- 60 people
- Sponsor
- Sohag University